{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Best overall response rate (Completed response \\[CR\\] + partial remission \\[PR\\]) during the first 8 cycles of treatment will be assessed using contrast-enhanced CT scans of the neck, chest, abdomen and pelvis, using the Revised Response Criteria for Malignant Lymphoma. In this study CR = complete disappearance of all detectable clinical evidence of disease, so involved lymph nodes had regressed on CT scan to normal size. PR = al least a 50% decrease in size of the involved lymph nodes measured on CT scans.","groups":[{"description":"Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.\n\nAvelumab: anti-PDL1 antibody","id":"OG000","title":"Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The per-protocol population was used ,defined as all patients recruited to the trial who started treatment","reportingStatus":"POSTED","timeFrame":"8 cycles (224 days)","title":"Best Overall Response Rate During the First 8 Cycles of Treatment","type":"PRIMARY","unitOfMeasure":"Participants"}